CymaBay Therapeutics, Inc.
CBAY · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $207 | $20 | $126 | $28 |
| Short-Term Investments | $188 | $115 | $61 | $118 |
| Receivables | $0 | $0 | $0 | $0 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $10 | $3 | $5 | $5 |
| Total Curr. Assets | $404 | $138 | $191 | $152 |
| Property Plant & Equip (Net) | $6 | $1 | $1 | $2 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $22 | $0 | $8 | $0 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $3 | $3 | $2 | $0 |
| Total NC Assets | $31 | $4 | $11 | $2 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $435 | $142 | $202 | $154 |
| Liabilities | – | – | – | – |
| Payables | $4 | $1 | $3 | $0 |
| Short-Term Debt | $10 | $1 | $1 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $2 | $0 | $0 | $0 |
| Other Curr. Liab. | $21 | $14 | $15 | $9 |
| Total Curr. Liab. | $37 | $15 | $18 | $10 |
| LT Debt | $104 | $90 | $51 | $1 |
| Deferred Rev, NC | $1 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $106 | $90 | $51 | $1 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $142 | $106 | $69 | $11 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$978 | -$873 | -$767 | -$677 |
| AOCI | $0 | -$0 | -$0 | $0 |
| Other Equity | $1,270 | $909 | $900 | $820 |
| Total Equity | $292 | $36 | $133 | $143 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $435 | $142 | $202 | $154 |
| Net Debt | -$92 | $71 | -$74 | -$26 |